FAQ

CYSLTR1 gene

Known as: CysLT(1), CysLT1, CYSLTR1 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1996-2018
051019962018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Montelukast targeting the cysteinyl leukotriene receptor 1 ameliorates Aβ1-42-induced memory impairment and neuroinflammatory and apoptotic responses in mice.
Montelukast, known as a cysteinyl leukotriene receptor 1 (CysLT1R) antagonist, is currently used for treatment of inflammatory… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
Antiasthmatic drugs targeting the cysteinyl leukotriene receptor 1 alleviate central nervous system inflammatory cell infiltration and pathogenesis of experimental autoimmune encephalomyelitis.
Cysteinyl leukotrienes (CysLTs) are potent proinflammatory mediators and are considered to play a key role in inflammatory… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2009
2009
Participation of leukotriene C(4) in the regulation of suicidal erythrocyte death.
Eryptosis, the suicidal death of erythrocytes, is characterized by cell shrinkage and cell membrane scrambling with… (More)
Is this relevant?
2007
2007
Chronic renal failure-induced multiple-organ injury in rats is alleviated by the selective CysLT1 receptor antagonist montelukast.
Chronic renal failure (CRF) is associated with oxidative stress that promotes production of reactive oxygen species and cytokine… (More)
Is this relevant?
2007
2007
Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism.
Cellular recruitment during inflammatory/immune responses is tightly regulated. The ability to dampen inflammation is imperative… (More)
Is this relevant?
2005
2005
Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice.
Our previous studies showed that cysteinyl leukotriene receptor-1 (CysLT1) antagonist pranlukast has a neuroprotective effect on… (More)
Is this relevant?
2005
2005
CysLT1 receptor is a target for extracellular nucleotide-induced heterologous desensitization: a possible feedback mechanism in inflammation.
Both cysteinyl-leukotrienes and extracellular nucleotides mediate inflammatory responses via specific G-protein-coupled receptors… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
Is this relevant?
2005
2005
CysLT1 leukotriene receptor antagonists inhibit the effects of nucleotides acting at P2Y receptors.
Montelukast and pranlukast are orally active leukotriene receptor antagonists selective for the CysLT1 receptor. Conversely, the… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis.
BACKGROUND Patients with asthma who have aspirin sensitivity have greater cysteinyl leukotriene production and greater airway… (More)
Is this relevant?
2001
2001
Chemotaxis and transendothelial migration of CD34(+) hematopoietic progenitor cells induced by the inflammatory mediator leukotriene D4 are mediated by the 7-transmembrane receptor CysLT1.
Recent studies suggest that bone marrow (BM)-derived chemotactic mediators such as chemokines play key roles in hematopoietic… (More)
Is this relevant?